PE20160121A1 - Formulaciones de factor viii recombinantes - Google Patents

Formulaciones de factor viii recombinantes

Info

Publication number
PE20160121A1
PE20160121A1 PE2015002012A PE2015002012A PE20160121A1 PE 20160121 A1 PE20160121 A1 PE 20160121A1 PE 2015002012 A PE2015002012 A PE 2015002012A PE 2015002012 A PE2015002012 A PE 2015002012A PE 20160121 A1 PE20160121 A1 PE 20160121A1
Authority
PE
Peru
Prior art keywords
factor viii
recombinant factor
viii formulations
formulations
recombinant
Prior art date
Application number
PE2015002012A
Other languages
English (en)
Spanish (es)
Inventor
Xinghang Ma
Deqian Wang
Nelly Tsvetkova
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20160121A1 publication Critical patent/PE20160121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2015002012A 2013-03-15 2014-03-11 Formulaciones de factor viii recombinantes PE20160121A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
PE20160121A1 true PE20160121A1 (es) 2016-03-03

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002012A PE20160121A1 (es) 2013-03-15 2014-03-11 Formulaciones de factor viii recombinantes

Country Status (17)

Country Link
US (1) US20160030524A1 (cg-RX-API-DMAC10.html)
EP (1) EP2970430A4 (cg-RX-API-DMAC10.html)
JP (1) JP2016518321A (cg-RX-API-DMAC10.html)
KR (1) KR20150132449A (cg-RX-API-DMAC10.html)
CN (1) CN105209487A (cg-RX-API-DMAC10.html)
AU (1) AU2014237111B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015022730A2 (cg-RX-API-DMAC10.html)
CA (1) CA2905739A1 (cg-RX-API-DMAC10.html)
HK (1) HK1213273A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015012905A (cg-RX-API-DMAC10.html)
PE (1) PE20160121A1 (cg-RX-API-DMAC10.html)
RU (1) RU2015144076A (cg-RX-API-DMAC10.html)
SG (2) SG10201803999UA (cg-RX-API-DMAC10.html)
TW (1) TW201521761A (cg-RX-API-DMAC10.html)
UY (1) UY35412A (cg-RX-API-DMAC10.html)
WO (1) WO2014150477A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201507684B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115561A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CN1339170A (zh) * 1999-02-01 2002-03-06 日本电气硝子株式会社 阴极射线管及其制造方法
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
EP1421539B1 (en) * 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
EP2385825B1 (en) * 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety

Also Published As

Publication number Publication date
EP2970430A1 (en) 2016-01-20
ZA201507684B (en) 2017-06-28
SG11201507618YA (en) 2015-10-29
CA2905739A1 (en) 2014-09-25
BR112015022730A2 (pt) 2017-10-31
SG10201803999UA (en) 2018-06-28
CN105209487A (zh) 2015-12-30
HK1213273A1 (zh) 2016-06-30
WO2014150477A1 (en) 2014-09-25
KR20150132449A (ko) 2015-11-25
US20160030524A1 (en) 2016-02-04
RU2015144076A (ru) 2017-04-24
AU2014237111A1 (en) 2015-10-08
MX2015012905A (es) 2016-06-16
UY35412A (es) 2014-10-31
AU2014237111B2 (en) 2018-06-21
EP2970430A4 (en) 2017-01-11
TW201521761A (zh) 2015-06-16
JP2016518321A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
MX2021005358A (es) Metodos y composiciones que comprenden polipeptidos recombinantes purificados.
UY34885A (es) Proteínas de unión anti-mesotelina
TR201900274T4 (tr) Geliştirilmiş adenovirüs formülasyonları.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34568A (es) Imidazoles y pirazoles fusionados sustituidos y sus usos
UY34817A (es) Tienopirimidinas
BR112015012907A2 (pt) composição de cuidado pessoal
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
UY34740A (es) Atomizador con agentes codificadores
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
IL236315A (en) Compositions comprising purified recombinant iduronate-2-sulfatase
CR20130521S (es) Aparato para peinar el cabello
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
UY34662A (es) Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas
HUE050362T2 (hu) Javított rekombináns fehérje expresszió hibrid CHEF1 promótert alkalmazva
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
UY34783A (es) Segadora
MX2015012905A (es) Formulaciones de factor viii recombinantes.
DK3572515T3 (da) Glykoproteinhormon langtidsvirkende superagonister
UY4242Q (es) Mesa

Legal Events

Date Code Title Description
FD Application declared void or lapsed